Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIPOR for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
NCT05211336Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2022
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax, ibrutinib, prednisone, obinutuzumab and lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Primary endpoint: Proportion of Participants Who Completed at Least 2 Cycles of VIPOR Without Stopping Due to Toxicity at 6 weeks. Started Apr 2022; status: active, not recruiting.
02
Drugs
venetoclaxibrutinibprednisoneobinutuzumablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05211336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05211336.